TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Molecular Partners Ag
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025

Molecular Partners announced progress on its Radio-DARPin MP0712 targeting DLL3, filed an IND application, and expects Phase 1 trial launch in late 2025. The company also reported promising results for MP0533, a multispecific T cell engager for AML, and maintains a strong financial position with cash runway until 2028.

Insights
MOLN   positive

Demonstrated clinical progress across multiple drug candidates, filed IND for MP0712, reported promising MP0533 trial results, and maintained strong financial position with cash runway until 2028